Business Context and Reporting Period
Company: Gyre Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2026
Reporting Period: Single event date (May 14, 2026)
Business Context: The registrant is a biopharmaceutical company incorporated in Delaware with its principal executive offices in San Diego, CA. Its common stock trades on The Nasdaq Capital Market under the symbol "GYRE".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a disclosure of a corporate event and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document serves solely to disclose a scheduled presentation at a scientific conference.
Guidance, Outlook, and Management Commentary
- Event Disclosure: On May 15, 2026, Gyre Therapeutics, Inc. will present a scientific presentation at a conference in Shanghai, China.
- Exhibit Reference: The presentation is furnished as Exhibit 99.1 and is incorporated by reference.
- Legal Disclaimer: The presentation is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. It shall not be deemed incorporated by reference in any other filing under the Exchange Act or the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the content of the scientific presentation (Exhibit 99.1) for potential updates on clinical trials or pipeline developments.
- Confirm the date and location of the upcoming conference presentation (May 15, 2026, Shanghai, China).
- Note that the presentation materials are not legally "filed" and carry different liability standards than standard SEC filings.